Factors affecting variability in distribution of tacrolimus in liver transplant recipients

British Journal of Clinical Pharmacology

Volumn 57, Issue 3, 2004, Pages 298-309

  Zahir, H ^a   McCaughan, C ^b   Gleeson, M ^b   Nand, R A ^a   McLachlan, A J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Blood distribution; Liver transplantation; Pharmacokinetics; Plasma protein binding; Tacrolimus; Therapeutic drug monitoring

Indexed keywords

3H DIHYDROTACROLIMUS; AZATHIOPRINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OROSOMUCOID; PREDNISOLONE; TACROLIMUS; UNCLASSIFIED DRUG;

ARTICLE; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; EQUILIBRIUM DIALYSIS; ERYTHROCYTE; FEMALE; GRAFT REJECTION; HEMATOCRIT; HEMODILUTION; HUMAN; LIPOPROTEIN DEFICIENCY; LIVER GRAFT; LYMPHOCYTE; MALE; PLASMA PROTEIN BINDING; PREDICTION; PRIORITY JOURNAL; RECIPIENT; SERUM; TREATMENT OUTCOME;

ADULT; AGED; ANALYSIS OF VARIANCE; ERYTHROCYTES; FEMALE; HEMATOCRIT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PLASMA; TACROLIMUS;

EID: 1542329748     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.02008.x     Document Type: Article

References (27)

1. Molinaro M, Regazzi MB, Pasquino S, et al. Pharmacokinetics of tacrolimus during the early phase after heart transplantation. Transplant Proc 2001; 33: 2386-9.
2. Abu-Elmagd K, Fung JJ, Alessiani M, et al. The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation 1991; 52: 71-7.
3. Winkler M, Jost U, Ringe B, Gubernatis G, Wonigeit K, Pichlmayr R. Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients. Transplant Proc 1991; 23: 3153-5.
4. Erden E, Warty V, Magnone M, Shapiro R, Demetris J, Randhawa P. Plasma FK506 levels in patients with histopathologically documented renal allograft rejection. Transplantation 1994; 58: 397-8.
5. Japanese FK 506 Study Group. Morphological characteristics of renal allografts showing renal dysfunction under FK 506 therapy: is graft biopsy available to reveal the morphological findings corresponding with FK 506 nephropathy? Transplant Proc 1993; 25: 624-7.
6. Kershner RP, Fitzsimmons WE. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 1996; 62: 920-6.
7. Backman L, Nicar M, Levy M, et al. Whole blood and plasma levels of FK 506 after liver transplantation: correlation with toxicity. Transplant Proc 1994; 26: 1804.
8. Venkataramanan R, Shaw LM, Sarkozi L, et al. Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients. J Clin Pharmacol 2001; 41: 542-51.
9. Zahir H, Nand RA, Tattam BN, Brown KF, McLachlan AJ. Validation of the methods to study distribution and protein binding of tacrolimus in human blood. J Pharmacol Toxicol Meth 2001; 46: 27-35.
10. Piekoszewski W, Jusko WJ. Plasma protein binding of tacrolimus in humans. J Pharm Sci 1993; 82: 340-1.
11. Warty V, Venkataramanan R, Zendehrouh P, et al. Distribution of FK 506 in plasma lipoproteins in transplant patients. Transplant Proc 1991; 23: 954-5.
12. Akhlaghi F, Keogh AM, Brown KF. Unbound cyclosporine and allograft rejection after heart transplantation. Transplantation 1999; 67: 54-9.
13. Boudinot FD, Jusko WJ. Fluid shifts and other factors affecting plasma protein binding of prednisolone by equilibrium dialysis. J Pharm Sci 1984; 73: 774-80.
14. Chung BH, Segrest JP, Ray MJ, et al. Single vertical spin density gradient ultracentrifugation. Meth Enzymol 1986; 128: 181-209.
15. Ormonde DG, de Boer WB, Kierath A, et al. Banff Schema for grading liver allograft rejection: utility in clinical practice. Liver Transpl Surg 1999; 5: 261-8.
16. Jusko WJ, Piekoszewski W, Klintmalm GB, et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 1995; 57: 281-90.
17. du Souich P, Verges J, Erill S. Plasma protein binding and pharmacological response. Clin Pharmacokinet 1993; 24: 435-40.
18. Takada K, Katayama N, Kiriyama A, Usuda H. Distribution characteristics of immunosuppressants FK506 and Cyclosporine A in the blood compartment. Biopharm Drug Dispos 1993; 14: 659-71.
19. Wasan KM, Pritchard PH, Ramaswamy M, Wong W, Donnachie EM, Brunner LJ. Differences in lipoprotein lipid concentration and composition modify the plasma distribution of Cyclosporine. Pharm Res 1997; 14: 1613-20.
20. Chow F-S, Piekoszewski W, Jusko W. Effect of haematocrit and albumin concentration on hepatic clearance of tacrolimus (FK506) during rabbit liver perfusion. Drug Metab Dispos 1997; 25: 610-16.
21. Wallemacq PE, Verbeeck RK. Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. Clin Pharmacokinet 2001; 40: 283-95.
22. Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995; 29: 404-30.
23. Kelly PA, Burckart GJ, Venkataramanan R. Tacrolimus, a new immunosuppressive agent. Am J Health-Syst Pharm 1995; 52: 1521-35.
24. Ichimaru N, Takahara S, Kokado Y, et al. Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. Atherosclerosis 2001; 158: 417-23.
25. Christians U, Jacobsen W, Benet LZ, Lampen A. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 2002; 41: 813-51.
26. Thomson AW, Bonham CA, Zeevi A. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit 1995; 17: 584-91.
27. Claesson K, Mayer AD, Squifflet J-P, et al. Lipoprotein patterns in renal transplant patients: a comparison between FK 506 and cyclosporine A patients. Transplant Proc 1998; 30: 1292-4.